公开(公告)号：JP2015522258A

公开(公告)日：2015-08-06

申请号：JP2015517433

申请日：2013-06-13

Applicant: ウェーン ステイト ユニヴァーシティWayne State University ,  ウェーン ステイト ユニヴァーシティWayne State University ,  ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティド バイ ザ セクレタリー、デパートメント オブ ヘルス アンド ヒューマン サービスシズ オフィス オブ テクノロジー トランスファー、ナショナル インスティテューツ オブ ヘルスTHE UNITED STATES OF AMERICA as represented by THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES OFFICE OF TECHNOLOGY TRANSFER,NATIONAL INSTITUTES OF HEALTH ,  ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティド バイ ザ セクレタリー、デパートメント オブ ヘルス アンド ヒューマン サービスシズ オフィス オブ テクノロジー トランスファー、ナショナル インスティテューツ オブ ヘルスTHE UNITED STATES OF AMERICA as represented by THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES OFFICE OF TECHNOLOGY TRANSFER,NATIONA ,  センメルワイス ユニヴァーシティSemmelweis University ,  センメルワイス ユニヴァーシティSemmelweis University ,  ジェネシス ゼラノスティック コラトルト フェレロスセグ タルササグGenesis Theranostix Korlatolt Felelossegu Tarsasag ,  ジェネシス ゼラノスティック コラトルト フェレロスセグ タルササグGenesis Theranostix Korlatolt Felelossegu Tarsasag

Inventor： タルカ、アディ、エル． ,  タン、ナンドール ,  フアス、ガボール ,  ケケシ、アドリエナ、カトリン ,  メイリ、ハムタル ,  パプ、ゾルタン ,  ロメロ、ロバート

IPC: C12Q1/68 ,  G01N33/50 ,  G01N33/68

Abstract: 子癇前症/HELLP症候群の初期試験を可能にする特異的バイオマーカーを開示し、妊婦の子癇前症を予測する方法を提供する。妊婦から採取した試料を特異的バイオマーカーの濃度について分析する手段を含むキットを開示する。【選択図】図2C

Abstract translation: 它公开特异性标志物，其允许先兆子痫/ HELLP综合征的初步测试，提供了一种预测孕妇先兆子痫的方法。 它公开了一种包括用于分析从孕妇截取的特异性生物标志物的样本的浓度的装置的试剂盒。 点域2C

公开(公告)号：JP6926195B2

公开(公告)日：2021-08-25

申请号：JP2019507068

申请日：2017-04-24

Applicant: トランスミューラル システムズ エルエルシー ,  Transmural Systems LLC ,  アメリカ合衆国 ,  The United States of America,as represented by the Secretary,Department of Health and Human Service(National Institutes of Health,Office of Technology Transfer)

Inventor： ラフィー,ナッサー ,  マクドナルド,スチュアート ,  レーダーマン,ロバート,ジェイ. ,  ロジャース,トビー ,  バソルド,レイニー ,  ラフィー,クーシャ

IPC: A61B17/00

公开(公告)号：JP2021180877A

公开(公告)日：2021-11-25

申请号：JP2021127471

申请日：2021-08-03

Applicant: トランスミューラル システムズ エルエルシー ,  Transmural Systems LLC ,  アメリカ合衆国 ,  The United States of America,as represented by the Secretary,Department of Health and Human Service(National Institutes of Health,Office of Technology Transfer)

Inventor： ラフィー,ナッサー ,  マクドナルド,スチュアート ,  レーダーマン,ロバート,ジェイ. ,  ロジャース,トビー ,  バソルド,レイニー ,  ラフィー,クーシャ

IPC: A61B17/00

Abstract: 【課題】経血管又は経室アクセスポートを容易に閉鎖できる様々なプロテーゼと、送達システムと、技術とを提供する。 【解決手段】複数の径方向拡張可能ディスクを含む。これは、容易に凝固できるようにし、管壁のなかの穿刺部からの漏洩を低減するか停止するかする材料で満たされてもよい。 【選択図】図1A

公开(公告)号：US20240405160A1

公开(公告)日：2024-12-05

申请号：US17839268

申请日：2022-06-13

Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN, Office of Technology Transfer

Inventor： Ayush PANDEY ,  Zetian MI

IPC: H01L33/14 ,  H01L33/00 ,  H01L33/02 ,  H01L33/06 ,  H01L33/32

Abstract: The presented devices and methods are directed to efficient and effective photon emission. In one embodiment, high-performance tunnel junction deep ultraviolet (UV) light-emitting diodes (LEDs) are created using plasma-assisted molecular beam epitaxy. The device heterostructure was grown under slightly Ga-rich conditions to promote the formation of nanoscale clusters in the active region. The nanoscale clusters can act as charge containment configurations. In one exemplary implementation, a device operates at approximately 255 nm light emission with a maximum external quantum efficiency (EPE) of 7.2% and wall-plug efficiency (WPE) of 4%, which are nearly one to two orders of magnitude higher than previously reported tunnel junction devices operating at this wavelength. The devices exhibit highly stable emission originating from highly localized carriers in Ga-rich regions formed in the active region, with nearly constant emission peak with increasing current density up to 200 A/cm2, due to the strong charge carrier confinement related to the presence of nanoclusters (e.g., Ga-rich) and radiative emission originating from highly localized carriers in Ga-rich regions formed in the active region

公开(公告)号：US20230404465A1

公开(公告)日：2023-12-21

申请号：US18135738

申请日：2023-04-18

Applicant: Galiana Technology Inc. ,  National Institutes of Health, Office of Technology Transfer

Inventor： Bruce T Hope ,  Mark A Wells ,  Gregory D Sutton

IPC: A61B5/00 ,  A61B5/07 ,  A61B5/1473 ,  A61B5/145

CPC classification number: A61B5/4064 ,  A61B5/076 ,  A61B5/1473 ,  A61B5/14546 ,  A61B5/6868 ,  A61B5/0031 ,  A61B2562/028 ,  A61B2560/0204 ,  A61B2562/0285 ,  Y10S977/774

Abstract: An intracellular monitoring device (IMD) that fits completely inside a living cell, and causes no significant impairment, to a cell's normal biological processes. The IMD monitors a cell for its level of a biological substance (e.g., calcium ion concentration) of interest. If the biological substance reaches or exceeds a threshold, the IMD transmits an electromagnetic signal, received by an antenna outside the cell. Each IMD has its electromagnetic signal encoded with a unique frequency. Detection of the frequency components, in the signals received by an antenna, permits identification of the source IMD's. A high calcium ion concentration is indicative of a strongly-activated cerebral cortex neuron. Brain tissue is relatively transparent to near infrared, making it a good frequency band, for the electromagnetic signals from neuron-monitoring IMD's. The near infrared of each IMD can be produced by quantum dots, powered by bioelectric catalysis triggered by high calcium ion concentration.

公开(公告)号：US20210079055A1

公开(公告)日：2021-03-18

申请号：US15930057

申请日：2020-05-12

Applicant: The Board of Trustees of the Leland Stanford Junior University ,  United States Department of Health and Human Services, Office of Technology Transfer, National Insti

Inventor： Christopher K. Garcia ,  Suman Mitra ,  Warren J. Leonard ,  Aaron M. Ring

IPC: C07K14/55 ,  A61K38/00

Abstract: Novel human interleukin-2 (IL-2) muteins or variants thereof are provided. In particular, provided are IL-2 muteins that have an increased binding capacity for IL-2Rβ receptor and a decreased binding capacity for IL-2Rγc receptor, as compared to wild-type IL-2. Such IL-2 muteins are useful, for example, as IL-2 partial agonist and antagonists in applications where reduction or inhibition of one or more IL-2 and/or IL-15 functions is useful (e.g., in the treatment of graft versus host disease (GVHD) and adult T cell leukemia). Also provided are nucleic acids encoding such IL-2 muteins, methods of making such IL-2 muteins, pharmaceutical compositions that include such IL-2 muteins and methods of treatment using such pharmaceutical compositions.

公开(公告)号：US10654905B2

公开(公告)日：2020-05-19

申请号：US16175709

申请日：2018-10-30

Applicant: The Board of Trustees of the Leland Stanford Junior University ,  United States Department of Health and Human Services, Office of Technology Transfer, National Institutes of Health

Inventor： Christopher K. Garcia ,  Suman Mitra ,  Warren J. Leonard ,  Aaron M. Ring

IPC: A61K38/20 ,  C07K14/55 ,  A61K38/00

Abstract: Novel human interleukin-2 (IL-2) muteins or variants thereof are provided. In particular, provided are IL-2 muteins that have an increased binding capacity for IL-2Rβ receptor and a decreased binding capacity for IL-2Rγc receptor, as compared to wild-type IL-2. Such IL-2 muteins are useful, for example, as IL-2 partial agonist and antagonists in applications where reduction or inhibition of one or more IL-2 and/or IL-15 functions is useful (e.g., in the treatment of graft versus host disease (GVHD) and adult T cell leukemia). Also provided are nucleic acids encoding such IL-2 muteins, methods of making such IL-2 muteins, pharmaceutical compositions that include such IL-2 muteins and methods of treatment using such pharmaceutical compositions.

公开(公告)号：US10590074B2

公开(公告)日：2020-03-17

申请号：US15830244

申请日：2017-12-04

Applicant: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services, Office of Technology Transfer, National Institutes of Health

Inventor： Amy Hauck Newman ,  Oluyomi M. Okunola-Bakare ,  Jianjing Cao

IPC: C07C323/60 ,  A61K45/06 ,  A61K31/135 ,  C07C317/44 ,  C07C317/28 ,  C07C323/25 ,  C07D295/08 ,  C07D295/088 ,  C07D295/108 ,  C07D295/185

Abstract: Disclosed herein are bisarylmethylthioacetamides and bisarylmethylthioethylamines useful as inhibitors of monoamine transporters. The compounds are potent and/or selective inhibitors of dopamine (DA), serotonin (5-HT), and/or norepinephrine (NE) reuptake via their respective transporters, DAT, SERT and NET. Also disclosed are methods for eliciting a wake-promoting or cognitive or attention enhancing effect and for treating substance use disorders, attention deficit (hyperactivity) disorder, depressive disorders, bipolar disorder or other neuropsychiatric disorders sleep disorders or cognitive impairment using the compounds.

公开(公告)号：US09896484B2

公开(公告)日：2018-02-20

申请号：US14887115

申请日：2015-10-19

Applicant: The United States of America as Represented by the Secretary of the Department of Health and Human Services, National Institutes of Health, Office of Technology Transfer

Inventor： Surender Khurana ,  Hana Golding

IPC: C07K14/005 ,  A61K39/145 ,  G01N33/559 ,  G01N33/569 ,  A61K39/12 ,  C12N7/00 ,  A61K39/00

CPC classification number: C07K14/005 ,  A61K39/00 ,  A61K39/12 ,  A61K39/145 ,  A61K2039/55566 ,  A61K2039/575 ,  C07K2319/21 ,  C12N7/00 ,  C12N2760/16034 ,  C12N2760/16122 ,  C12N2760/16134 ,  C12N2760/16143 ,  C12N2760/16152 ,  G01N33/559 ,  G01N33/56983 ,  G01N2333/11

Abstract: The present invention includes influenza Hemagglutinin protein fragments that fold properly when expressed in bacteria.

公开(公告)号：US20170067974A1

公开(公告)日：2017-03-09

申请号：US15309336

申请日：2015-05-07

Applicant: Joseph A. Murphy-Boesch ,  Stephen Dodd ,  Chunqi Qian ,  Alan Koretsky ,  OFFICE OF TECHNOLOGY TRANSFER, NATIONAL INSTITUTES OF HEALTH

Inventor： Joseph A. Murphy-Boesch ,  Stephen Dodd ,  Chunqi Qian ,  Alan Koretsky

IPC: G01R33/36 ,  G01R33/561

CPC classification number: G01R33/3621 ,  G01R33/3642 ,  G01R33/3692 ,  G01R33/5616

Abstract: A novel MRI-compatible amplifier design uses positive feedback from a low-noise Field-Effect Transistor to amplify the signal current within a resonant NMR coil. The amplified signal current in this low-power circuit produces RF flux can be coupled out to receiving loops positioned externally without significant loss in sensitivity. In other aspects, the amplifier may be remotely powered by external resonant loops, a small non-magnetic battery, or optical power, such that the NMR coil can be positioned during highly invasive procedures such as for surgical resection of tumors in deep-lying tissues to develop high-resolution images.

Abstract translation: 一种新颖的MRI兼容放大器设计使用来自低噪声场效应晶体管的正反馈来放大谐振NMR线圈内的信号电流。 该低功率电路中放大的信号电流产生的RF通量可以耦合到外部定位的接收回路，而灵敏度没有显着的损失。 在其他方面，放大器可以由外部谐振回路，小型非磁性电池或光学功率远程供电，使得NMR线圈可以在高侵入性程序中定位，例如用于在深层组织中手术切除肿瘤 开发高分辨率图像。